TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04111783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POU protocol ultrasound
Description: The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
Study: NCT02895490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive a DVD containing educational information and communication skills
Study: NCT01519843

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation TMS
Description: TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
Study: NCT03047538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin, Amlodipine, Perindopril
Description: To compare free and fixed combination of atorvastatin, perindopril, amlodipine
Study: NCT04321499

Intervention type: GENETIC
Intervention: lung cancer
Description: PCR for SHOX2 and PTGER4

Intervention type: GENETIC
Intervention: lung cancer
Description: PCR for SHOX2 and PTGER4
Study: NCT02112552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00555191

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet restriction
Description: each meal should contain less than 2 gm fructose
Study: NCT02587286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gather app
Description: Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
Study: NCT02417181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care provided by Physician Assistants
Description: Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
Study: NCT00114777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept Less Intensive Regimen (LI)
Description: solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept More Intensive Regimen (MI)
Description: solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
Study: NCT03447145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3203
Description: dose escalation, 2/4/6/10/14/18mg/m2
Study: NCT02122952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVXS-101
Description: Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVXS-101
Description: Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
Study: NCT01284764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride
Description: Mosapride 10mg, one dosage, once evening of the day before the endoscopy
Study: NCT00629239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4818
Description: Dry Powder, inhalation, b.i.d., 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00793065

Intervention type: OTHER
Intervention: Electronic health record (EHR)
Description: Computer-based system that allows physicians to access and manage patient records electronically.

Intervention type: OTHER
Intervention: Electronic health record (EHR)
Description: Computer-based system that allows physicians to access and manage patient records electronically.

Intervention type: OTHER
Intervention: Medical Home redesign
Description: Implementation of NCQA Level III Medical Home
Study: NCT02663505

Intervention type: PROCEDURE
Intervention: Patients receiving the surgery planned for them
Description: For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient.
Study: NCT02162563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX/ FOLFIRI with bevacizumab
Description: FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX/ FOLFIRI with bevacizumab
Description: FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI with bevacizumab
Description: FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/ FOLFIRI with panitumumab
Description: FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
Study: NCT03044561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: 25 mg orally, 4 times per day for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: orally, 4 times per day for 21 days
Study: NCT02049879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids injection
Description: A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
Study: NCT02112175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT01471327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-240563
Description: 10mg, 75mg, 250mg and 750mg IV, single dose on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-240563
Description: 10mg, 75mg, 250mg and 750mg IV, single dose on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-240563
Description: 10mg, 75mg, 250mg and 750mg IV, single dose on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-240563
Description: 10mg, 75mg, 250mg and 750mg IV, single dose on Day 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline IV, single dose at Day 1
Study: NCT02128490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat IR
Description: Febuxostat IR over-encapsulated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat IR
Description: Febuxostat IR over-encapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat over-encapsulated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat over-encapsulated capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat placebo
Description: Febuxostat IR and XR placebo-matching capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study: NCT04240743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cephalomedullary nail
Description: For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cephalomedullary nail
Description: For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sliding hip screw
Description: For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sliding hip screw
Description: For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
Study: NCT03361670

Intervention type: OTHER
Intervention: Observational Study
Study: NCT01753492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ologen
Study: NCT00224016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 1.3, 2.6, 3.9 mg/day transdermal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: 5 to 15 mg/day immediate release or extended release tablets, or syrup
Study: NCT04684030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system(CGMS)
Description: Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring of blood glucose (conventional fingerpricking method)
Description: Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
Study: NCT02895490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication skills training
Description: Receive a DVD containing educational information and communication skills

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive information about the LINC group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03809637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, cisplatin
Description: Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
Study: NCT04324463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Beta
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: oral medication
Study: NCT01554982

Intervention type: DRUG
Group type: OTHER
Intervention: ferric citrate
Description: Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
Study: NCT04118985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation and health behavior change intervention
Description: Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-implementation
Description: Self-implementation of cognitive rehabilitation and health behavior change recommendations
Study: NCT00641160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Dose Level #1 PO for at least 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Dose Level #2 PO for at least 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Dose Level #3 PO for at least 7 days
Study: NCT02377830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-bed cycle ergometer (Restorative Therapies RT300 Supine)
Study: NCT03129763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 100mmHg capsule pressure expansion
Description: With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
Study: NCT01499186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Vibration
Description: The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
Study: NCT03855371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m2/d, intravenously, d1-d5, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
Study: NCT00032487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
Study: NCT02377830

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy
Description: activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
Study: NCT00033735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven
Description: Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
Study: NCT01364415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Study: NCT04215094

Intervention type: DIAGNOSTIC_TEST
Intervention: postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun
Description: All patients in Intracranial Infection group were cured with antibiotic treatment

Intervention type: DIAGNOSTIC_TEST
Intervention: postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun
Description: All patients in Intracranial Infection group were cured with antibiotic treatment
Study: NCT00718133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometry (Pony spirometer)
Description: Spirometry at rest
Study: NCT02240134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention (Tx1)
Description: The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Filtration Unit Treatment (Tx2)
Description: A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Intervention (Tx3)
Description: Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter.
Study: NCT00391599

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: enema

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enema